16/06/2013
|
Early treatment may do more harm than good in poor regions
While U.S. treatment guidelines recommend universal treatment of HIV, the benefits of such a policy may not outweigh the costs in resource-poor areas around the globe. Three researchers from Johns Hopkins University published a paper in Clinical Infectious Diseases, arguing that the limited scope and inconsistent availability of antiretrovirals (ARVs), as well as diminished laboratory...
Read more... 
|
|
: |
16/06/2013
|
Sign-on request: Letter to Gilead - tenefovir alafenamide fumarate (TAF)
Treatment Action Group (TAG), in collaboration with HIV i-Base and Project Inform, is requesting organizational and individual sign-ons to a letter urging Gilead Sciences to develop a stand-alone formulation of tenofovir alafenamide fumarate (TAF), an experimental prodrug of the nucleotide reverse transcriptase inhibitor tenofovir.
We are concerned that Gilead’s...
Read more...
|
|
|
16/06/2013
|
Fighting the HIV epidemic in the Islamic world
In many Muslim countries strong moral views on HIV prevail including within the medical profession, giving rise to deeply rooted stigma and discrimination against people with HIV/AIDS and those perceived to be at high risk of infection.This prejudice forces the people most in need of HIV prevention and treatment programmes away from services. Many countries and policy makers are unable to...
Read more...
|
|
|
16/06/2013
|
A cure for HIV: where we've been, and where we're headed
Developments towards a cure for HIV are exciting—for scientists, for clinicians, and most importantly, for patients. But we need to be realistic. Finding a cure will be a long and tough road, and will take many more years to achieve. We are at the very beginning, although many now believe that it might be possible to find a cure, at least for a small proportion of infected people....
Read more...
|
|
|
16/06/2013
|
AbbVie says it can be first with new hepatitis C drugs
AbbVie Inc. (ABBV) said it can win the race against Gilead Sciences Inc. (GILD) to bring to market a new generation of all-oral hepatitis C drugs.
AbbVie’s trial for an unnamed multidrug therapy is in the last of three stages typically required for U.S. approval and is moving quickly, Scott Brun, the company’s head of drug development, told investors today at a...
Read more...
|
|
